Leerink Partnrs Raises Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Kura Oncology in a note issued to investors on Thursday, November 21st. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($2.19) for the year, up from their previous forecast of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

Several other analysts have also recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Jefferies Financial Group dropped their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, November 21st. UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Bank of America decreased their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Price Performance

KURA opened at $10.96 on Monday. The stock has a market capitalization of $852.25 million, a PE ratio of -4.64 and a beta of 0.86. The stock’s 50 day moving average price is $17.88 and its 200-day moving average price is $19.67. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in Kura Oncology during the third quarter valued at $25,000. Aaron Wealth Advisors LLC lifted its holdings in Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after purchasing an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after purchasing an additional 2,940 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.